查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1917783

緩釋藥物遞送市場－2026-2031年預測

Controlled Release Drug Delivery Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計緩釋藥物輸送市場將從 2025 年的 539.02 億美元成長到 2031 年的 941.38 億美元，複合年成長率為 9.74%。

緩釋藥物遞送系統透過確保藥物濃度穩定，進而維持治療效果並提高慢性病管理的用藥依從性，推動市場發展。不斷增加的研發投入正在推動新技術的發展，這些新技術能夠實現精準且持續的藥物釋放。學名藥生產的擴大為患者提供了更具成本效益的緩釋藥物選擇。人口老化也促使人們尋求更安全、用藥頻率更低的長期治療方案。

緩釋藥物遞送系統可在較長時間內維持最佳活性成分濃度，從而提高療效並最大限度地減少濃度波動。這些平台可減少給藥頻率，提高病患依從性和便利性，同時也能減少因峰谷波動引起的副作用。在慢性病負擔日益加重、監管支持、技術進步以及老年人老化導致持續治療需求增加等因素的推動下，該市場正穩步擴張。

關鍵成長要素包括緩釋製劑的固有優勢，例如維持治療濃度、減少給藥頻率和提高療效，這些優勢對於需要持續治療的疾病尤其重要。慢性病盛行率的不斷上升，使得可靠的長效製劑成為最佳化治療方案和減少併發症的必要手段。學名藥的普及使得品牌藥等效的緩釋製劑能夠以可負擔的價格廣泛供應，並符合確保生物等效性和品質的監管途徑。機構研發投入的增加正在加速遞送機制的創新，包括多顆粒、基質和滲透系統。人口快速老化，生理機能下降，以及用藥依從性方面的挑戰，導致多種藥物聯合使用，並促使人們尋求減少給藥頻率、提高耐受性的給藥方案，以維持生活品質。

從區域來看，由於慢性病發病率上升、醫療費用支出高企、監管政策支持、人口老齡化以及強大的創新生態系統，北美預計將實現顯著成長並保持穩定的市場佔有率。該地區蓬勃發展的非專利產業也進一步推動了緩釋製劑的應用。

主要企業包括 Adare Pharma Solutions，這是一家全球 CDMO，專門從事使用多顆粒、基質系統、滲透平台和包衣顆粒的緩釋口服劑型，提供個性化的緩釋特性；Colorcon 在薄膜包衣技術方面表現出色，例如 Opadry®，可提高固態劑型的耐久性、外觀和控釋控制釋放； Pembrolizumab）、Januvia®（sitagliptin）、 Gardasil（人類乳突病毒(HPV)疫苗）和 ProQuad®（麻疹-水痘合併疫苗）等產品。

總體而言，在慢性病日益增多和人口結構變化的背景下，人們期望解決依從性、治療方法最佳化和可及性方面的障礙，這推動了市場強勁成長。聚合物、塗層和滲透技術的不斷進步正在擴大其臨床效用範圍。

本報告的主要優勢：

  • 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

企業如何使用我們的報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

研究範圍：

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

5. 按技術分類的緩釋藥物遞送市場

  • 介紹
  • 微膠囊化
  • 經皮吸收
  • 定向投放
  • 其他

第6章 緩釋藥物遞送市場：依釋放機制分類

  • 介紹
  • 聚合物基體系
  • 微儲庫控制藥物輸送系統
  • 回饋控制藥物傳輸系統
  • 啟動控制藥物遞送系統
  • 化學活化

第7章 緩釋藥物遞送市場：依應用領域分類

  • 介紹
  • 定量噴霧吸入器
  • 注射
  • 經皮和眼用貼劑
  • 其他

8. 按地區分類的控釋藥物遞送市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Adare Pharma Solutions
  • Merck and Co., Inc
  • Colorcon
  • Coating Place
  • GlaxoSmithKline PLC
  • Lonza
  • Bayer Healthcare LLC
  • Orbis Biosciences Inc.
  • Alkermes PLC
  • Pfizer Inc.

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615754

Controlled Release Drug Delivery Market is forecasted to rise at a 9.74% CAGR, reaching USD 94.138 billion in 2031 from USD 53.902 billion in 2025.

The controlled release drug delivery market is advancing as systems ensure steady therapeutic levels, enhancing compliance in chronic disease management. Rising R&D investments are fueling novel technologies for precise, prolonged release profiles. Growth in generic production is delivering cost-effective controlled-release options. Aging populations are amplifying demand for safer, less frequent dosing regimens in long-term therapies.

Controlled release drug delivery systems maintain optimal API concentrations over extended periods, minimizing fluctuations and improving efficacy. These platforms reduce dosing frequency, boosting patient adherence and convenience while mitigating side effects from peak-trough variations. The market is expanding steadily, supported by chronic disease burden, regulatory encouragement, technological progress, and demographic shifts toward elderly cohorts requiring sustained treatments.

Key growth drivers include the inherent benefits of controlled release, such as sustained therapeutic levels, fewer administrations, and enhanced outcomes, particularly valuable for conditions demanding consistent management. Escalating chronic disease prevalence necessitates reliable, long-acting formulations to optimize control and reduce complications. Expansion of the generic segment enables broader access to affordable controlled-release equivalents of branded drugs, aligned with regulatory pathways ensuring bioequivalence and quality. Heightened R&D expenditure, backed by institutional funding, accelerates innovations in delivery mechanisms like multiparticulates, matrix, and osmotic systems. The burgeoning aging population, with diminished physiological resilience and adherence challenges, favors low-frequency, tolerable dosing to support polypharmacy and quality of life.

Geographically, North America is projected for significant growth and share retention, attributed to elevated chronic disease rates, substantial healthcare spending, supportive regulations, geriatric demographics, and robust innovation ecosystem. The region's thriving generic industry further catalyzes controlled-release adoption.

Leading companies include Adare Pharma Solutions, a global CDMO specializing in oral dosage forms with controlled release via multiparticulates, matrix systems, osmotic platforms, and coated pellets for tailored, extended profiles. Colorcon excels in film coatings like Opadry(R) to enhance durability, aesthetics, and release control in solid dosages. Merck & Co., Inc. develops and markets pharmaceuticals incorporating advanced delivery, exemplified by products like Keytruda(R) (pembrolizumab), Januvia(R) (sitagliptin), Gardasil(R) (HPV vaccine), and ProQuad(R) (measles/varicella vaccine).

Overall, the market is progressing robustly, positioned to address adherence barriers, therapeutic optimization, and accessibility amid chronic disease escalation and demographic transitions, with ongoing advancements in polymer, coating, and osmotic technologies broadening clinical utility.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Controlled Release Drug Delivery Market Segmentation

  • By Technology
  • Micro Encapsulation
  • Transdermal
  • Targeted Delivery
  • Others
  • By Release Mechanism
  • Polymer Based Systems
  • Micro Reservoir Partition Controlled Drug Delivery Systems
  • Feedback Regulated Drug Delivery Systems
  • Activation-modulated Drug Delivery Systems
  • Chemically Activated
  • By Application
  • Metered Dose Inhalers
  • Injectable
  • Transdermal and Ocular Patches
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CONTROLLED RELEASE DRUG DELIVERY MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Micro Encapsulation
  • 5.3. Transdermal
  • 5.4. Targeted delivery
  • 5.5. Others

6. CONTROLLED RELEASE DRUG DELIVERY MARKET BY RELEASE MECHANISM

  • 6.1. Introduction
  • 6.2. Polymer Based Systems
  • 6.3. Micro Reservoir Partition Controlled Drug Delivery Systems
  • 6.4. Feedback Regulated Drug Delivery Systems
  • 6.5. Activation-modulated Drug Delivery Systems
  • 6.6. Chemically Activated

7. CONTROLLED RELEASE DRUG DELIVERY MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Metered Dose Inhalers
  • 7.3. Injectable
  • 7.4. Transdermal and Ocular Patches
  • 7.5. Others

8. CONTROLLED RELEASE DRUG DELIVERY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Adare Pharma Solutions
  • 10.2. Merck and Co., Inc
  • 10.3. Colorcon
  • 10.4. Coating Place
  • 10.5. GlaxoSmithKline PLC
  • 10.6. Lonza
  • 10.7. Bayer Healthcare LLC
  • 10.8. Orbis Biosciences Inc.
  • 10.9. Alkermes PLC
  • 10.10. Pfizer Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations